Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma

By Ayllon Jorge   Beuselinck Benoit   Morel Alexandre   Barrascout Eduardo   Medioni Jacques   Scotte Florian   Oudard Stééphane  

Cancer Investigation, Vol. 29, Iss. 4, 2011-04 ,pp. : 282-285

Informa Healthcare

Access to resources Recommend Favorite

Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line

By      

Molecular Medicine Reports, Vol. 10, Iss. 4, 2014-01 ,pp. : 2065-2072

Spandidos Publications

Access to resources Recommend Favorite

Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 3, 2014-09 ,pp. : 382-393

Bentham Science Publishers

Access to resources Recommend Favorite

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

By Bourrié Bernard  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1488-1499

Informa Healthcare

Access to resources Recommend Favorite

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

By Valabrega Giorgio  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite